Targets › SLC6A6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Mediates sodium- and chloride-dependent transport of taurine, a key amino acid. Taurine acts as an anti-aging agent by reducing cellular senescence and combating oxidative stress: levels decline with age and supplementation has been shown to extend lifespan (By similarity). (UniProt, P31641)
Open in Phaseline: the race on SLC6A6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shandong Cancer Hospital and Institute | Taurine Amino acid with antioxidant and cytoprotective properties; taurine transporter substrate | SLC6A6 | Phase 1 | To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients | Sep 2027 |
To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients (1)
–
Shandong Cancer Hospital and Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.